InProTher logo

InProTher

InProTher is creating advanced cancer immunotherapies based on pre-clinical models with Professor Holst.

2-10 employees · est. 2018

VS
iOmx Therapeutics AG logo

iOmx Therapeutics AG

Developing next-generation targeted cancer immunotherapy treatments

53 employees · est. 2016 · Germany

iOmx Therapeutics AG is the older company (2018 vs 2016); iOmx Therapeutics AG is the larger of the two.

Side-by-Side Comparison

InProTher iOmx Therapeutics AG
Founded
2018 2016 older
Headquarters
Not tracked yet Germany
Employees
2-10 53 larger
Industry
Biotechnology, Health Care Biopharma, Health Care, Pharmaceutical
Funding Stage
Seed Series B
Total Funding
$8.50M $105.00M
Funding Rounds
3 2
Services
Not tracked yet Development of targeted cancer immunotherapy treatments, Translating immune evasion biology into drug programs, Innovative drug pipeline, Novel immune checkpoint target identification
Target Customers
Not tracked yet Cancer patients, Healthcare providers, Oncologists, Pharmaceutical companies, Biotech investors
Taxonomy
Cancer Immunotherapy, Pre-clinical Models, Advanced Therapies, Immune Checkpoint Inhibitors, Tumor Immunity, Research Collaboration, Cancer Therapy Development, Immunotherapy Success, Professor Holst, Associate Professor Holst, Cancer Research, Cancer Treatment Innovations Immuno-oncology, Targeted Cancer Therapy, Immune Checkpoint Modulators, Drug Development, Pre-clinical Development, Clinical Development, Tumor Immunology, Checkpoint Inhibitors, Tumor Cell Screening, Immune Resistance Mechanisms, Novel Target Identification, Immune Response Reactivation, Biotechnology Start-up, Therapeutic Portfolio
Website
inprother.com iomx.com
InProTher logo

About InProTher

InProTher is a biotechnology startup founded in 2018, dedicated to creating cutting-edge cancer immunotherapies. The company's slogan, "InProTher is creating advanced cancer immunotherapies based on pre-clinical models with Professor Holst," succinctly captures its mission. With a focus on pioneerin...

iOmx Therapeutics AG logo

About iOmx Therapeutics AG

iOmx Therapeutics AG is positioned at the forefront of the immuno-oncology sector, striving to revolutionize cancer treatment with its next-generation targeted cancer immunotherapy solutions. Founded in 2016 and headquartered in Germany, iOmx utilizes its robust technology platform to advance a port...

We will tell you when either one moves

BounceWatch watches InProTher and iOmx Therapeutics AG for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at InProTher and iOmx Therapeutics AG — by email.

Frequently Asked Questions

InProTher — InProTher is creating advanced cancer immunotherapies based on pre-clinical models with Professor Holst.. iOmx Therapeutics AG — Developing next-generation targeted cancer immunotherapy treatments. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
InProTher has raised $8.50M while iOmx Therapeutics AG has raised $105.00M.
InProTher and iOmx Therapeutics AG operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare InProTher with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at InProTher on 11 Sep 2024, and iOmx Therapeutics AG on 28 May 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy